Evolving therapeutic landscape of advanced hepatocellular carcinoma
C Yang, H Zhang, L Zhang, AX Zhu… - Nature reviews …, 2023 - nature.com
Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …
A large proportion of patients with HCC are diagnosed at advanced stages and are only …
Pathogenesis and current treatment strategies of hepatocellular carcinoma
D Tümen, P Heumann, K Gülow, CN Demirci… - Biomedicines, 2022 - mdpi.com
Hepatocellular carcinoma (HCC) is the most frequent liver cancer with high lethality and low
five-year survival rates leading to a substantial worldwide burden for healthcare systems …
five-year survival rates leading to a substantial worldwide burden for healthcare systems …
Hepatitis B virus-associated hepatocellular carcinoma
Hepatitis B virus (HBV) is DNA-based virus, member of the Hepadnaviridae family, which
can cause liver disease and increased risk of hepatocellular carcinoma (HCC) in infected …
can cause liver disease and increased risk of hepatocellular carcinoma (HCC) in infected …
Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function
The number of effective systemic therapies for the treatment of advanced hepatocellular
carcinoma (HCC) is rapidly increasing, and the advent of immunotherapy has changed the …
carcinoma (HCC) is rapidly increasing, and the advent of immunotherapy has changed the …
[HTML][HTML] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
M Persano, M Rimini, T Tada, G Suda… - European Journal of …, 2023 - Elsevier
Introduction The aim of this retrospective proof-of-concept study was to compare different
second-line treatments for patients with hepatocellular carcinoma and progressive disease …
second-line treatments for patients with hepatocellular carcinoma and progressive disease …
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: an international observational study
Abstract Background and Aims Different approaches are available after the progression of
disease (PD) to immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) …
disease (PD) to immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) …
Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
A Cammarota, V Zanuso, GF Manfredi… - Therapeutic …, 2023 - journals.sagepub.com
The treatment landscape of advanced hepatocellular carcinoma (HCC) has broadened with
immune checkpoint inhibitors (ICIs) setting a novel standard of care. With the increased …
immune checkpoint inhibitors (ICIs) setting a novel standard of care. With the increased …
The new era of systemic treatment for hepatocellular carcinoma: from the first line to the optimal sequence
Hepatocellular carcinoma (HCC) represents the most common primary liver cancer and is
considered a major global health problem as one of the leading causes of cancer-related …
considered a major global health problem as one of the leading causes of cancer-related …
Current therapeutic strategies for hepatocellular carcinoma in Japan
M Kudo - Liver cancer, 2023 - karger.com
The treatment outcomes of patients with hepatocellular carcinoma (HCC) in Japan have
improved dramatically over the past 40 years and are probably the best in the world …
improved dramatically over the past 40 years and are probably the best in the world …
[HTML][HTML] Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma
Y Liu, J Ma, X Wang, P Liu, C Cai, Y Han… - Computers in Biology …, 2023 - Elsevier
Abstract Background RAB7A (RAS-related in Brain 7A) is an important member of the RAS
oncogene family. However, the correlation between RAB7A and the development and …
oncogene family. However, the correlation between RAB7A and the development and …